Ingen Technologies Inc (IGNT)

[B7$4]

"IGNT News" Press Release Source: Ingen Technologies, Inc. On Thursday February 18, 2010, 8:15 am

YUCAIPA, Calif., Feb. 18, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced today that the CEO and Chairman of the Board, Scott R. Sand, has issued the following statement.

"Ingen Technologies is focused on increasing the sales and marketing of its respiratory product line. We have passed Stage-I of our ISO Certification audit, and expect to pass Stage-II on March 1, 2010. This ISO certification opens doors to Europe, Asia, Canada and Australia where our products are needed more, and where we currently have back-orders pending ISO certification. COPD is the 4th cause of death in the USA and Canada, and the first leading cause of death in Europe and Asia, and this is why there is a greater demand of our Smart Nasal Cannula with Oxyview, and our new I-Pulse Oximeter. We expect to meet our 2010 projections of $11M in sales. Israel is our newest distribution partner, as we discuss details with Elul Medical Assistance Services Ltd."

"There is no reverse split authorized or being discussed. We have strong investment commitments to assist the company with a stock buy-back program. In order to comply with the forbearance agreement with the N.I.R. Group, we will seek majority vote from our shareholders to increase the authorized so that we can pay off the balance of the note owed to the various funds managed by the N.I.R. Group and move forward with the share buy-back program. We have signed an aggressive PR contract with Accelerize New Media and the OTCRoadshow.com to support and strengthen shareholder value over the next few months. Currently the company has paid off the majority of its debts, and has reduced the NIR debt down from $4.5M to $2.2M in the past 5 months. When this debt is cured, we will begin the share buy-back program. We continue to have a sufficient cash reserve, and our product sales continue to show a steady incline, despite the fact that we have not gained ISO certification as of now."

"Our pending GSA contracts are expected to be approved very soon, and these contracts will also greatly improve our distribution and product sales. KGMA Business Solutions has recently begun introducing our products and negotiating national distribution contracts for VA Hospitals and the Department of Defense. We will make an announcement in 2 weeks regarding their progress."

"We are not out of the woods just yet, however. We have a strong commitment to our shareholders and to the success of this company, and there is no doubt that our medical products are now on the way to creating the revenues and recognition that they deserve in the marketplace. The company will be introducing another new proprietary and innovative product in April-2010 for the drug industry. The heart of our success lies within the risks we have taken and our belief in these new medical products and success for this company. With all of this said, we continue to seek the support from our shareholders, and look for success in the near future to come," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.

http://www.cdc.gov/nchs/FASTATS/lcod.htm

http://www.healthnews.com/disease-illness/leading-causes-death-europe-1109.html

http://www.healthnews.com/medical-updates/leading-causes-death-asia-1440.html

http://idealbody4life.com/the-leading-causes-of-death-in-australia

http://www.ingen-tech.com/

http://www.smartnasalcannula.com/

http://www.ipulseoximeter.com/

About Ingen:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472